Cambrex Charles City Inc, based in U.S.A, is a pharmaceutical company that stands out with its certifications from FDA and EDQM.
They are recognized for Cambrex is an innovative life sciences company with a refreshingly human approach.
One of their notable products is NICOTINE POLACRILEX, 15%, USP, with a corresponding US DMF Number 16166.
Remarkably, this DMF maintains an Active status since its submission on October 01, 2002, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of December 26, 2012, and payment made on December 12, 2012, indicating their dedication to facilitating drug approvals, Categorized as Type II